---
title: "Vaxart, Inc. (VXRT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VXRT.US.md"
symbol: "VXRT.US"
name: "Vaxart, Inc."
industry: "Biotechnology"
datetime: "2026-04-14T20:55:59.652Z"
locales:
  - [en](https://longbridge.com/en/quote/VXRT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VXRT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VXRT.US.md)
---

# Vaxart, Inc. (VXRT.US)

## Company Overview

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [vaxart.com](https://vaxart.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-14T04:30:18.000Z

**Overall: B (0.26)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 58 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 726.68% |  |
| Net Profit YoY | 124.39% |  |
| P/B Ratio | 1.92 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 168574365.76 |  |
| Revenue | 237258000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 22.26% | A |
| Profit Margin | 6.88% | B |
| Gross Margin | 15.04% | D |
| Revenue YoY | 726.68% | A |
| Net Profit YoY | 124.39% | A |
| Total Assets YoY | 11.83% | B |
| Net Assets YoY | 49.00% | A |
| Cash Flow Margin | 47.25% | C |
| OCF YoY | 726.68% | A |
| Turnover | 1.35 | A |
| Gearing Ratio | 52.82% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Vaxart, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "726.68%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "124.39%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.92",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "168574365.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "237258000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "22.26%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "6.88%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "15.04%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "726.68%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "124.39%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "11.83%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "49.00%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "47.25%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "726.68%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.35",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "52.82%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 10.32 | 24/393 | 10.00 | 9.35 | 9.16 |
| PB | 1.92 | 176/393 | 3.48 | 2.52 | 1.90 |
| PS (TTM) | 0.71 | 16/393 | 2.07 | 1.06 | 0.68 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | C | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-13T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.71 |
| Highest Target | 4.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VXRT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VXRT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VXRT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VXRT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**